Literature DB >> 3124343

The influence of cyclosporin A on the vascular permeability of the pancreatic islets and on diabetes induced by multiple low doses of streptozotocin in the mouse.

L Jansson1, S Sandler.   

Abstract

The aim of the present study was to investigate the influence of cyclosporin A on the course of multiple low dose streptozotocin induced diabetes in mice, an animal model for human type I diabetes mellitus. C57BL/Ks mice were treated on five consecutive days with intraperitoneal injections of streptozotocin or citiric acid buffer. Thirty min before the injections the animals were given cyclosporin A (10 or 50 mg/kg body weight) or saline. Cyclosporin A did not protect against the hypoglycaemia and at the higher dose it potentiated the diabetogenic effect. Furthermore, cyclosporin A did not affect the development of insulitis when the pancreatic glands were examined by light microscopy. Using a technique for monitoring vascular permeability in vivo with the aid of the pigment Monastral Blue B, it was found that the development of diabetes was accompanied by an increased vascular leakage. Control animals treated with cyclosporin A also showed an increased islet staining with Monastral Blue B. The data indicate that cyclosporin A potentiates diabetes induced by low doses of streptozotocin. This can be attributed to a direct toxic effect of cyclosporin A on the pancreatic B-cells and may also be due to an increased vascular leakage induced by cyclosporin A. The latter would allow an increased migration of inflammatory cells into the islets and the consequent release of B-cytotoxic substances.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3124343     DOI: 10.1007/bf00737146

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  25 in total

1.  Cytokines cause functional and structural damage to isolated islets of Langerhans.

Authors:  T Mandrup-Poulsen; K Bendtzen; J H Nielsen; G Bendixen; J Nerup
Journal:  Allergy       Date:  1985-08       Impact factor: 13.146

2.  Cyclosporine for treatment of early type I diabetes: preliminary results.

Authors:  C R Stiller; A Laupacis; J Dupre; M R Jenner; P A Keown; W Rodger; B M Wolfe
Journal:  N Engl J Med       Date:  1983-05-19       Impact factor: 91.245

3.  Effect of cyclosporin A on low-dose streptozotocin diabetes in mice.

Authors:  H Kolb; M Oschilewski; E Schwab; U Oschilewski; U Kiesel
Journal:  Diabetes Res       Date:  1985-07

4.  Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats.

Authors:  U Helmchen; W E Schmidt; E G Siegel; W Creutzfeldt
Journal:  Diabetologia       Date:  1984-09       Impact factor: 10.122

5.  Protection by dimethyl urea against hyperglycaemia, but not insulitis, in low-dose streptozotocin-induced diabetes in the mouse.

Authors:  S Sandler
Journal:  Diabetologia       Date:  1984-05       Impact factor: 10.122

6.  Vascular permeability of pancreatic islets after administration of streptozotocin.

Authors:  S Sandler; L Jansson
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

7.  Cyclosporine: five years' experience in cadaveric renal transplantation.

Authors:  R M Merion; D J White; S Thiru; D B Evans; R Y Calne
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

8.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus.

Authors:  A A Like; A A Rossini
Journal:  Science       Date:  1976-07-30       Impact factor: 47.728

9.  Cyclosporin A in cadaveric organ transplantation.

Authors:  R Y Calne; D J White; D B Evans; S Thiru; R G Henderson; D V Hamilton; K Rolles; P McMaster; T J Duffy; B R MacDougall; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-21

10.  Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats.

Authors:  R B Nussenblatt; M M Rodrigues; W B Wacker; S J Cevario; M C Salinas-Carmona; I Gery
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

View more
  3 in total

1.  Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus.

Authors:  E Strandell; D L Eizirik; S Sandler
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Role of infiltrating T cells for impaired glucose metabolism in pancreatic islets isolated from non-obese diabetic mice.

Authors:  E Strandell; S Sandler; C Boitard; D L Eizirik
Journal:  Diabetologia       Date:  1992-10       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.